Andrea Ciaranello MD MPH, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infectious Disease Transmission, Vertical | 19 | 2020 | 1353 | 3.390 |
Why?
|
| HIV Infections | 58 | 2021 | 17531 | 2.720 |
Why?
|
| Anti-HIV Agents | 25 | 2020 | 4558 | 1.720 |
Why?
|
| Anti-Retroviral Agents | 10 | 2020 | 1786 | 1.440 |
Why?
|
| Pregnancy Complications, Infectious | 13 | 2020 | 2184 | 1.410 |
Why?
|
| Cost-Benefit Analysis | 20 | 2021 | 5531 | 1.110 |
Why?
|
| Early Diagnosis | 9 | 2020 | 1186 | 1.090 |
Why?
|
| Breast Feeding | 9 | 2020 | 1363 | 0.850 |
Why?
|
| CD4 Lymphocyte Count | 10 | 2021 | 2586 | 0.780 |
Why?
|
| World Health Organization | 9 | 2020 | 1326 | 0.740 |
Why?
|
| South Africa | 13 | 2020 | 1868 | 0.680 |
Why?
|
| Zimbabwe | 6 | 2020 | 135 | 0.660 |
Why?
|
| Models, Economic | 2 | 2020 | 716 | 0.650 |
Why?
|
| Health Care Costs | 10 | 2020 | 3241 | 0.600 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 1218 | 0.600 |
Why?
|
| Infant | 30 | 2020 | 36426 | 0.570 |
Why?
|
| Ritonavir | 4 | 2016 | 331 | 0.560 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2019 | 468 | 0.540 |
Why?
|
| Nevirapine | 3 | 2015 | 273 | 0.530 |
Why?
|
| Models, Theoretical | 7 | 2019 | 3560 | 0.510 |
Why?
|
| Life Expectancy | 7 | 2019 | 1247 | 0.470 |
Why?
|
| Infant, Newborn | 21 | 2020 | 26380 | 0.470 |
Why?
|
| Health Resources | 4 | 2020 | 950 | 0.470 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2019 | 1899 | 0.460 |
Why?
|
| HIV | 3 | 2018 | 1587 | 0.460 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2020 | 746 | 0.450 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 116 | 0.440 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 788 | 0.420 |
Why?
|
| Infant Mortality | 1 | 2018 | 752 | 0.420 |
Why?
|
| Pregnancy | 24 | 2020 | 30230 | 0.400 |
Why?
|
| Epidemics | 1 | 2018 | 514 | 0.400 |
Why?
|
| Computer Simulation | 5 | 2019 | 6251 | 0.370 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 2020 | 2204 | 0.330 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 560 | 0.330 |
Why?
|
| Infant Care | 2 | 2020 | 181 | 0.310 |
Why?
|
| Pyrimidinones | 1 | 2011 | 384 | 0.300 |
Why?
|
| Mass Screening | 3 | 2020 | 5449 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2019 | 295 | 0.290 |
Why?
|
| Premature Birth | 1 | 2019 | 1830 | 0.280 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 856 | 0.270 |
Why?
|
| Halfway Houses | 1 | 2006 | 11 | 0.270 |
Why?
|
| Costs and Cost Analysis | 3 | 2020 | 1666 | 0.270 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2006 | 47 | 0.270 |
Why?
|
| Drug Costs | 1 | 2014 | 1194 | 0.250 |
Why?
|
| Young Adult | 20 | 2021 | 59857 | 0.250 |
Why?
|
| Africa | 4 | 2020 | 725 | 0.250 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2021 | 1740 | 0.240 |
Why?
|
| Female | 51 | 2020 | 396141 | 0.230 |
Why?
|
| Humans | 70 | 2021 | 765926 | 0.220 |
Why?
|
| Viral Load | 7 | 2020 | 3385 | 0.220 |
Why?
|
| Perinatal Care | 2 | 2018 | 243 | 0.220 |
Why?
|
| HIV-1 | 7 | 2020 | 6945 | 0.210 |
Why?
|
| Body Weight | 1 | 2014 | 4627 | 0.210 |
Why?
|
| Adolescent | 22 | 2021 | 88811 | 0.210 |
Why?
|
| Child, Preschool | 14 | 2020 | 42510 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7423 | 0.200 |
Why?
|
| Guidelines as Topic | 3 | 2014 | 1394 | 0.200 |
Why?
|
| Adult | 32 | 2021 | 223088 | 0.190 |
Why?
|
| Child | 19 | 2020 | 80568 | 0.190 |
Why?
|
| Exanthema | 1 | 2006 | 503 | 0.190 |
Why?
|
| Tuberculosis | 1 | 2014 | 2009 | 0.190 |
Why?
|
| Zidovudine | 2 | 2015 | 626 | 0.180 |
Why?
|
| Neural Tube Defects | 2 | 2019 | 256 | 0.170 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 143 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 5509 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2020 | 101 | 0.170 |
Why?
|
| Africa, Eastern | 2 | 2020 | 76 | 0.160 |
Why?
|
| Audiovisual Aids | 1 | 2020 | 98 | 0.160 |
Why?
|
| Nurse-Patient Relations | 1 | 2019 | 101 | 0.150 |
Why?
|
| Postpartum Period | 3 | 2020 | 1195 | 0.150 |
Why?
|
| Male | 33 | 2021 | 363815 | 0.150 |
Why?
|
| Models, Biological | 2 | 2016 | 9443 | 0.150 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3109 | 0.150 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3231 | 0.150 |
Why?
|
| Erythema Infectiosum | 1 | 2018 | 15 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2020 | 2745 | 0.140 |
Why?
|
| RNA, Viral | 4 | 2016 | 2866 | 0.140 |
Why?
|
| Africa South of the Sahara | 4 | 2020 | 751 | 0.140 |
Why?
|
| Viremia | 2 | 2018 | 727 | 0.140 |
Why?
|
| Benzoxazines | 1 | 2019 | 320 | 0.140 |
Why?
|
| New York City | 1 | 2019 | 736 | 0.140 |
Why?
|
| Postnatal Care | 1 | 2019 | 273 | 0.140 |
Why?
|
| Counseling | 2 | 2020 | 1551 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2018 | 147 | 0.130 |
Why?
|
| Child Health Services | 1 | 2020 | 645 | 0.120 |
Why?
|
| Policy Making | 1 | 2018 | 546 | 0.120 |
Why?
|
| Cote d'Ivoire | 4 | 2016 | 65 | 0.110 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2016 | 164 | 0.110 |
Why?
|
| Virus Replication | 2 | 2020 | 2450 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 1342 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2019 | 10086 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 614 | 0.100 |
Why?
|
| HIV-2 | 1 | 2013 | 156 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2020 | 41680 | 0.100 |
Why?
|
| Prenatal Care | 1 | 2019 | 1158 | 0.100 |
Why?
|
| Oxazines | 3 | 2019 | 358 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 1506 | 0.090 |
Why?
|
| Silicones | 1 | 2012 | 228 | 0.090 |
Why?
|
| Outpatients | 1 | 2019 | 1595 | 0.090 |
Why?
|
| Africa, Southern | 2 | 2020 | 60 | 0.090 |
Why?
|
| Central America | 2 | 2020 | 69 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2014 | 663 | 0.090 |
Why?
|
| Family Planning Services | 1 | 2013 | 277 | 0.090 |
Why?
|
| South America | 2 | 2020 | 180 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 2170 | 0.090 |
Why?
|
| Caribbean Region | 2 | 2020 | 193 | 0.080 |
Why?
|
| Medication Adherence | 3 | 2020 | 2190 | 0.080 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2009 | 30 | 0.080 |
Why?
|
| Developing Countries | 3 | 2011 | 2913 | 0.080 |
Why?
|
| Health Facilities | 1 | 2014 | 577 | 0.080 |
Why?
|
| Consent Forms | 1 | 2009 | 55 | 0.080 |
Why?
|
| Bottle Feeding | 1 | 2008 | 67 | 0.080 |
Why?
|
| Pyridones | 3 | 2019 | 816 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 6058 | 0.080 |
Why?
|
| Anemia | 1 | 2018 | 1514 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2013 | 867 | 0.070 |
Why?
|
| Incidence | 5 | 2020 | 21513 | 0.070 |
Why?
|
| National Health Programs | 1 | 2011 | 443 | 0.070 |
Why?
|
| Health Services | 1 | 2013 | 756 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2713 | 0.070 |
Why?
|
| United States | 5 | 2021 | 72909 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2019 | 65194 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2008 | 374 | 0.070 |
Why?
|
| Pandemics | 3 | 2020 | 8721 | 0.060 |
Why?
|
| Developed Countries | 1 | 2009 | 452 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2017 | 5088 | 0.060 |
Why?
|
| Arm | 1 | 2008 | 588 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14643 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 291 | 0.060 |
Why?
|
| Social Work | 1 | 2006 | 158 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 878 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2010 | 960 | 0.060 |
Why?
|
| Retrospective Studies | 9 | 2020 | 81537 | 0.050 |
Why?
|
| Piperazines | 3 | 2019 | 2546 | 0.050 |
Why?
|
| Device Removal | 1 | 2008 | 643 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2008 | 956 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1435 | 0.050 |
Why?
|
| Software | 1 | 2017 | 4462 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2008 | 497 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2020 | 2515 | 0.050 |
Why?
|
| California | 1 | 2006 | 1435 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8725 | 0.050 |
Why?
|
| Africa, Central | 1 | 2020 | 8 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 40097 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2020 | 115 | 0.040 |
Why?
|
| Pneumonia | 1 | 2012 | 2158 | 0.040 |
Why?
|
| Pediatrics | 2 | 2012 | 3609 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 111 | 0.040 |
Why?
|
| Organizational Case Studies | 1 | 2020 | 301 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 136 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 8037 | 0.040 |
Why?
|
| Fertilization | 1 | 2020 | 197 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 630 | 0.040 |
Why?
|
| Malawi | 1 | 2020 | 313 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2006 | 1832 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 74850 | 0.040 |
Why?
|
| Mozambique | 1 | 2018 | 55 | 0.040 |
Why?
|
| Alkynes | 1 | 2019 | 326 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 1456 | 0.040 |
Why?
|
| Parvovirus B19, Human | 1 | 2018 | 42 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 335 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 382 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 436 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2006 | 2502 | 0.040 |
Why?
|
| Boston | 2 | 2020 | 9334 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 120 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2013 | 2653 | 0.030 |
Why?
|
| Botswana | 1 | 2019 | 1057 | 0.030 |
Why?
|
| Fetal Death | 1 | 2018 | 434 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 124 | 0.030 |
Why?
|
| Middle Aged | 7 | 2019 | 223016 | 0.030 |
Why?
|
| Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2020 | 838 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 538 | 0.030 |
Why?
|
| Pregnant Women | 1 | 2020 | 576 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 1729 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Age Distribution | 1 | 2020 | 2864 | 0.030 |
Why?
|
| China | 1 | 2020 | 2383 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 430 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2020 | 18962 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2016 | 587 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Lung | 1 | 2012 | 10046 | 0.030 |
Why?
|
| Africa, Western | 1 | 2013 | 160 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 737 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 984 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2016 | 618 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 865 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4851 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10380 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 15645 | 0.020 |
Why?
|
| Prevalence | 2 | 2020 | 15828 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 39228 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2013 | 292 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2206 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 1184 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 26282 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2018 | 1432 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2591 | 0.020 |
Why?
|
| Fever | 1 | 2018 | 1607 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 682 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2782 | 0.020 |
Why?
|
| Headache | 1 | 2018 | 1261 | 0.020 |
Why?
|
| Genotype | 2 | 2013 | 13026 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3768 | 0.020 |
Why?
|
| Transsexualism | 1 | 2012 | 210 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 3078 | 0.020 |
Why?
|
| Cough | 1 | 2012 | 598 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4405 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2318 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 445 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10810 | 0.020 |
Why?
|
| Gestational Age | 1 | 2016 | 3616 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4782 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 1970 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4641 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 7599 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3385 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2016 | 2693 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6306 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 1752 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4520 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2018 | 2281 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2970 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2016 | 54807 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2020 | 8060 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9525 | 0.010 |
Why?
|
| Dyspnea | 1 | 2012 | 1351 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15540 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2530 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2018 | 3847 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12973 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 3108 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12822 | 0.010 |
Why?
|
| Research Design | 1 | 2018 | 6204 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2778 | 0.010 |
Why?
|
| Smoking | 1 | 2017 | 9082 | 0.010 |
Why?
|
| Mortality | 1 | 2011 | 2910 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1791 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24275 | 0.010 |
Why?
|
| Aged | 3 | 2017 | 171163 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2504 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13614 | 0.010 |
Why?
|
| Registries | 1 | 2008 | 8346 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 168735 | 0.000 |
Why?
|